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It is estimated that around 2.3 million new HIV infections 
occur worldwide every year and there are now about 35 million 
people currently living with the disease.1 This is an increase from 
previous years, which stems from the success in the widening of 
access to anti-retroviral drugs which has led to a higher 
prevalence as infection rates rise whilst mortality has decreased. 
Despite this success, current combination therapies still do not 
treat latent viral reservoirs within cells,2 requiring dosing 
regimens which ultimately lead to resistant HIV strains, 
necessitating the constant development of new innovative drugs 
to combat resistance.3  
There are many ‘druggable’ targets in the HIV life cycle, 
which have led to a number of drug classes such as fusion/CCR5, 
reverse transcription, intergrase and protease inhibitors amongst 
others. However, whilst these can provide effective control of the 
virus, they do not lead to eradication of HIV from the infected 
patient.4 One potential target for this, is the mutation resistant 
nucleocapsid protein which plays a crucial role throughout the 
viral life cycle by promoting strand annealing by tRNA3Lys to the 
primer binding site,5-7 the integration of viral DNA into the host 
chromosome8-9 and in the dimerisation and packaging of full-
length viral RNA into new virions and as such, represents an 
attractive proposition for the development of new drug classes.8-9 
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Figure 1. Previously reported NCp7 small molecule Zn2+ abstractors.  
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Surprisingly, this biological target is not species-dependent 
and amongst non-human vertebrates, feline immunodeficiency 
virus (FIV) infection in cats is perhaps the closest biological 
model of HIV infection in humans, with an analogous AIDS-like 
disease progression.10 The prevalence of FIV is around 11% 
worldwide, although there are significant regional variations and 
there is no known cure.11 FIV and HIV are closely related to 
other lentiviruses including the simian12 (SIV) and equine13 
(EIAV) variants, each of which is a species-specific virus using 
analogous protein in the viral life cycle.14 Previous compounds 
that were shown to act against the nucleocapsid protein of HIV-1 
(NCp7) (Fig. 1) have shown encouraging results but so far have 
failed to make the progression to late stage clinical trials.15-20 
As a result of the similarity and sequence overlap between the 
nucleocapsid protein of HIV and FIV, we recently initiated a 
research program to develop compounds that could target this 
key protein. We previously described the results of our first class 
of compounds against this key target with a series of 
bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrroles that 
showed promising activity against FIV, but were limited by their 
chemical tractability.21 Mutagenesis studies have shown that this 
target is intolerant of mutation and transcription errors, via 
deletion or modification of either of the two zinc fingers and 
leads to virus inactivation.22 Our longer-term objective is 
therefore the development of a highly active, non-toxic drug 
candidate against the nucleocapsid protein, which would 
represent a major breakthrough in the treatment of HIV in 
humans and FIV in cats.  
The nucleocapsid protein is a short nucleic acid binding 
protein which contains two key zinc fingers, with each derived 
from one histidine and three cysteine residues, tetrahedrally 
coordinated to Zn2+.22-24 This motif is conserved among nearly all 
known lentiviruses and various electrophilic agents have been 
investigated for their effects to cause HIV-1 inhibition, by 
covalent modification of the nucleophilic zinc finger cysteine 
thiolates leading to zinc ejection from either zinc finger as shown 
below (Fig. 2).25  
 
Figure 2. Proposed mechanism of the electrophilic ejection of Zn2+ by 
fused 1,2,5,6-tetrathiocine 9. 
 
The electrophilic nature of a number of previously reported 
compounds (Fig. 1), corresponds to their activity against the 
nucleocapsid protein and successful Zn2+ ejection. The next 
phase of our research program therefore focused on the design of 
compounds that could exploit this characteristic (Fig. 3).26-29 
Fused 1,2,5,6-tetrathiocines are ideal in this sense as they contain 
two disulfide motifs in an eight-membered heterocyclic ring 
formation, with the result that both are in close proximity to each 
other. Tetrathiocines conjugated with aromatic rings have shown 
high anti-microbial activity toward Candida albicans30 and anti-
fungicidal activity toward Staphylococcus aureus, Escherichia 
coli, and Saccharomyces cerevisiae.31  
The likely mechanism of action for Zn2+ ejection is 
nucleophilic attack on the Zn-S bond by compound 9, with a 
form of redox reaction between the cysteine thiolates followed by 
successful chelation and subsequent ejection (Figs. 2 and 3). 
There is a requirement for a second functionality in this proposed 
mechanism, which prompted us to look into self-contained 
compounds that contain two disulfide functional groups. This 
could potentially lead to a decrease in dose and a corresponding 
increase in potency. However synthetic methods have generally 
been limited to the oxidation of poorly available starting 
compounds such as vicinal 1,2-dithioles and their derivatives32-35 
or desulfurisation of benzo-1,2,3-trithioles.36-37 
 
Figure 3. Modeling of potential interaction of 9, docked using QM-
polarized ligand docking and Fukui+ function in the Schrödinger Suite 
2013, locally visualized to proposed reactive sulfur (gray colour used 
for isovalue 0.001 and green for 0.005 green) with the NCp7 of HIV as a 
model for the FIV NCp.  
The synthetic strategy we employed for their syntheses, 
involved reaction of sulfur monochloride with activated aromatic 
derivatives and nucleophilic heterocycles as shown in Scheme 1. 
Sulfur monochloride was employed in our synthetic strategy as it 
could be used in a one pot protocol either alone or activated with 
1,4-diazobicyclo[2.2.2]octane (DABCO).38,39 Our approach 
enabled us to rapidly produce a number of various fused 1,2,5,6- 
tetrathiocine analogues in high yields and under mild conditions. 
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Scheme 1. Reagents and conditions - (a) acetic acid, S2Cl2, 48 hr, rt, then 
SnCl2/MeOH; (b) S2Cl2, DABCO, CHCl3, -35 oC, then 48 hr, rt and 
Et3N, 3 hr, reflux; (c) NaCN, MeCN, 1 hr. 
Fused 1,2,5,6-tetrathiocines were prepared by treatment of 
sulfur monochloride with ortho-disubstituted aromatic substrates 
(8, 10a-b) in acetic acid, followed by trituration with methanolic 
tin(II)chloride, producing the corresponding 1,2,5,6-
tetrathiocines (9, 11a-b) in yields similar to that previously 
reported.40,41 The DABCO activated approach used a two-step 
procedure, involving production of 1,2,3,4,5-pentathiepins, 
  
which underwent reduction to form fused 1,2,5,6-
tetrathiocines.42,43 This was achieved by dropwise addition of 
sulfur monochloride to a solution of DABCO in chloroform at -
35 oC to form a 1:2 complex after 1 hour, which was followed by 
the addition of various heterocycles 12a-f and the reaction 
allowed to stir at room temperature for 48 hours yielding the 
corresponding pentathiepino-fused heterocycles 13a-f.44-46 13a-f 
were suspended in acetonitrile and treated with sodium cyanide 
for 1 hour after which the fused 1,2,5,6-tetrathiocines (14a-f) 
formed in good yield (54-74%).47,48 When the same method was 
applied with compound 15 to form the asymmetric 
indolopentathiepine 16 two regioisomers  - 17, were formed as a 
1:1 inseparable mixture as shown (Sch. 1).47  
With obtention of the planned chemical targets, the biological 
testing was split into two stages, with the first looking at toxicity 
over two stages, where the first ruled out high cytotoxic 
compounds with a short assay over 24 hours, exposing Crandell 
Rees Feline Kidney cells (CrFK) to three higher concentrations 
(100 µM - 1 µM) of the test compounds. The second stage gave 
an enhanced longer-term cytotoxicity screen and an anti-FIV 
profile that was realised over seven days at six concentrations 
ranging between 100 µM and 1 nM, using an IL-2 independent 
feline lymphoblastoid cell line (FL-4).  
The 24-hour assay on CRFK cells ruled out any major 
toxicity issues, as cytotoxic compounds removed at an early stage 
can prevent later false positives, with an MTT assay used to 
quantify the level of cell viability.49 Compounds that passed the 
initial 24-hour exposure test with viability above 75% at 10 µM 
on CrFK cells were then screened against FIV. 
FL-4 cells infected with FIV were exposed to the compounds 
over a period of seven days and sampled every day and at each of 
six concentrations. To determine the extent of viral replication, 
viral RNA was isolated from cell culture supernatants in a 
MagNA Pure LC System using the Total Nucleic Acid Isolation 
Kit (Roche Applied Science) and were subsequently used to 
determine the viral load by a quantitative real-time reverse-
transcription polymerase chain reaction (RT-qPCR) for FIV 
RNA.50 The screening results were also checked for their 
viability using the MTT assay to rule out any toxicity effects 
validating the RT-qPCR result. 
Table 1. Results of cytotoxic screening and FIV viral loading of the 
fused-tetrathiocine derivatives.  
Compound CrFKa  CC50b  EC50b TIc clogPd 
Number Viability µM µM     
9 75.35 >100 0.0309 >3236 4.14 
11a 77.01 5.79 0.0932 62.1 4.75 
11b 91.07 >100 0.0689 >1451 4.67 
13a >100 4.23 0.1687 25.1 5.89 
14a >100 >100 >100 1 9.43 
14b >100 >100 0.2045 >489 5.96 
14c >100 >100 >100 1 7.01 
14d >100 >100 14.500 >6.9 8.43 
14e >100 >100 60.660 1.6 6.74 
14f >100 58.22 3.0800 18.9 8.62 
17 >100 >100 0.0429 >2331 5.85 
AZT >100 >100 5.3100 >18.8 -0.16 
Raltegravir  >100 >100 0.0100 >10000 1.16 
aSample concentration of 10 µM of compound on CrFK cells for 24 hours – 
percentage viability; bGeometric mean, each concentration tested in triplicate 
after 7 days as a difference of the untreated FL-4 cells; cTherapeutic index is 
CC50/EC50, which is the ratio of toxicity to activity; dCalculated using 
ChemBioDraw Ultra 12. 
The results obtained, indicated that the para-disubstituted 
fused 1,2,5,6-tetrathiocines (9, 11a-b & 17) gave generally 
favorable toxicity profiles and good activity, with most CC50s 
above 100 µM and activities in the low nanomolar range (Tab. 1). 
1,2,5,6-Tetrathiocines with fused heterocyclic rings (14a-f) were 
not as effective possibly due to the higher cLogP considering the 
ratio of activity to toxicity. Once the cLogP increases above six, 
activity decreases and is much closer to the toxicity profile of the 
compound, which is perhaps to be expected as solubility of the 
compounds reduces in the assay medium. It is interesting to note 
that testing of intermediate 13a gave reasonable results with a 
therapeutic index of 25, which could be used as a potential lead 
compound in a new series. The activity of AZT and Raltegravir 
are consistent with previous reports in FIV/HIV.51,52 
Overall, these results indicate that the nucleocapsid protein of 
FIV can be targeted effectively with symmetrical dual 
functionality compounds with high efficacy. The relative 
simplicity and tractability of the synthetic approach makes these 
compounds attractive for further development and optimization.  
The high therapeutic index and potency of 9 indicates that there 
is potential for further development of this series of compounds 
to improve the toxicity profiles and bioavailability. The results of 
our investigations into this will be reported in due course.  
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N, 9.71. Found: C, 50.25; H, 7.18; N, 9.62; 1H NMR (Pyr-d5 500 MHz), 
δ: 1.22 (t, 24H, CH3, J = 7.0 Hz), 3.20 (q, 16H, CH2, J = 7.0 Hz); 13C 
NMR (Pyr-d5 100 MHz), δ: 13.4 (CH3), 50.8 (CH2), 122.6 (C), 153.9 (C); 
MS (EI, 70 eV), m/z (%): 576 ([M]+, 12), 512 (20), 288 (45), 259 (100), 
244 (40). HMRS: found m/z 577.1665; calc. for C24H40N4S6 [M+H]+ 
577.1655.  
1,3,6,8-Tetrachloro-2,7-diethyl[1,2,5,6]tetrathiocino[3,4-c:7,8-
c']dipyrrole, (14c): Yellow crystals (70%, 0.32 g); m.p. 310-312 °C; 
Anal. Calcd. for C12H10Cl4N2S4: C, 31.87; H, 2.23; N, 6.19. Found: C, 
31.72; H, 2.04; N, 6.32.; 1H NMR (Pyr-d5 500 MHz) δ: 1.01 (t, 6H, J = 
7.3 Hz, CH3), 3.73 (q, 4H, J = 7.3 Hz, CH2); 13C NMR (Pyr-d5 100 MHz) 
δ: 14.9 (CH3), 42.2 (CH2), 118.0 (C), 135.5 (C); MS (EI, 70 eV), m/z 
(%): 450 ([M]+, 20), 392 (2), 390 (20), 388 (42), 386 (28), 29 (100); 
HMRS: found m/z: 450.8554; [M+H]+ calc. for C12H11Cl4N2S4 450.8554. 
2,7-Bis(tert-butyl)[1,2,5,6]tetrathiocino[3,4-c:7,8-c´]dipyrrole (14d): 
Yellow crystals (74%, 0.27 g); m.p. 190-192 °C; Anal. Calcd. For 
C16H22N2S4: C, 51.85; H, 5.98; N, 7.56; Found: C, 51.98; H, 6.20; N, 
7.90; 1H NMR (CDCl3 500 Hz) δ: 1.51 (s, 18H, CH3), 7.06 (s, 4H, CH); 
13C NMR (CDCl3 100 MHz) δ: 30.27 (CH3), 125.38 (CH), 56.16 (C), 
119.43 (C); MS (EI, 70 eV), m/z (%): 370 (M+, 90), 306 (90), 250 (65), 
194 (100), 64 (90); HMRS: found m/z: 370.0654: [M]+ calc. for 
C16H22N2S4 370.0666. 
1,3,6,8-Tetramethyl-2,7-diethyl[1,2,5,6]tetrathiocino[3,4-c:7,8-
c']dipyrrole, (14e): Yellow crystals (73%, 0.27 g); m.p. 293-295 °C; 
Anal. Calcd. for C16H22N2S4: C, 51.85; H, 5.98; N, 7.56.; Found: C, 
51.72; H, 5.81; N, 7.82; 1H NMR (Pyr-d5 500 MHz) δ: 0.94 (t, 6H, J = 
7.3 Hz, CH3), 2.29 (s, 6H, CH3), 2.35 (s, 3H, CH3), 2.41 (s, 3H, CH3), 
3.53 (q, 4H, J = 7.3 Hz, CH2), 0.94 (t, 6H, J = 7.3 Hz, CH3), 2.29 (s, 6H, 
CH3), 2.35 (s, 3H, Me), 2.41 (s, 3H, Me), 3.53 (q, 4H, J = 7.3 Hz, CH2); 
13C NMR (Pyr-d5 100 MHz), δ: 11.0 (CH3); 15.7 (CH3); 40.1 (CH2); 
117.2, 134.6 (two quaternary C atoms); MS (EI, 70 eV), m/z (%): 370 
([M]+, 23), 338 (37), 306 (58), 273 (29), 217 (28), 184 (45), 152 (52), 42 
(100); HMRS: found m/z 371.0737: [M+H]+ calc. for C16H23N2S4 
371.0744.  
1,3,6,8-Tetramethyl-2,7-dibenzyl[1,2,5,6]tetrathiocino[3,4-c:7,8-
c']dipyrrole, (14f): Yellow crystals (71%, 0.35 g); m.p. 305-307 °C;  
Anal. Calcd. for C26H26N2S4: C, 63.12; H, 5.30; N, 5.66. Found: C, 63.33; 
H, 5.42; N, 5.31; 1H NMR (Pyr-d5 500 MHz) δ: 2.29 (s, 12H, CH3); 4.95 
(s, 4H, CH2), 6.95 (d, 4H, J =7.3 Hz, CH), 7.24-7.29 (m, 6H, CH); 13C 
NMR (Pyr-d5 100 MHz) δ: 11.40 (CH3), 48.62 (CH2), 117.25 (C atom), 
126.5 (CH), 128.1 (CH), 129.6 (CH), 135.8 (CH), 137.8 (C); MS (EI, 70 
eV), m/z (%): 494 ([M]+, 8), 430 (18), 339 (15), 248 (23), 91 (100); 
HMRS: found m/z 495.1061: [M+H]+ calc. for C26H27N2S4 495.1057. 
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